Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Risk Assessment Needs IoM Report To Synthesize Research – CERTs

Executive Summary

The Institute of Medicine should study the current state of pharmaceutical risk assessment and recommend methodological and research improvements, participants in a Centers for Education & Research on Therapeutics risk assessment workshop suggested
Advertisement

Related Content

IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
Rx Risk Descriptions Need To Be Standardized, FDA’s Galson Tells CERTs
CERTS presentation on drug risk workshops
DIA Annual Meeting, In Brief
FDA Plans Three Risk Management-Related Guidances Under PDUFA III
Medication Error Study By USP Will Examine Computerized Entry Systems
Medication Error Study By USP Will Examine Computerized Entry Systems
FDA Postmarketing Strategy Draws On 1980 Melmon Commission Report
Merck Builds Risk Management Into Drug Development; Hires FDA’s Honi
FDA/PhRMA May Create Database Of Hepatotoxins
Advertisement
UsernamePublicRestriction

Register

PS040113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel